Current diagnostic and therapeutic strategies in cardiac amyloidosis – According to the position statement of the ESC Working Group of Myocardial and Pericardail Diseases in 2021

█ Review

DOI: 10.26430/CHUNGARICA.2022.52.2.130

Authors:
Takács Hedvig, Nagy Viktória, Rácz Gergely, Kormányos Árpád, Polestyuk Bianka, Schvartz Noémi, Gyenes Nándor, Dézsi Lívia, Radics Bence, Iványi Béla, Sepp Róbert
Szegedi Tudományegyetem, Belgyógyászati Klinika, Non-Invazív Kardiológiai Részleg, Szeged
Levelezési cím:
Dr. Takács Hedvig, 6725 Szeged, Semmelweis u. 8. E-mail: takacs.hedvig88@gmail.com

Summary

Cardiac amyloidosis is a serious, progressive, infiltrative disease caused by the abnormally folded amyloid fibril deposits in the myocardium. The underlying causes could be haematological or chronic inflammatory diseases, and also rare genetic variants. However, the cause of amyloidosis in the elderly population is unknown. Thanks to the advanced imaging techniques and the new effective therapeutic possibilities, cardiac amyloidosis nowadays is more frequently diagnosed. In recent years many diagnostic and therapeutic guides have been issued. In 2021 the ESC Working Group of Myocardial and Pericardial Diseases published a position statement about the recent diagnostic and therapeutic strategies in cardiac amyloidosis.

ISSUE: CARDIOLOGIA HUNGARICA | 2022 | VOLUME 52, ISSUE 2

click here to read the full article

click here to read the pdf

---